Types of immunotherapeutic treatments. Tumor immunotherapy approaches can be broadly categorized as (A) cell therapies (CAR-T), (B) immune checkpoint inhibitor therapies, (C) drug nano-delivery, and (D) oncolytic virus therapies. (A) In CAR-T, for example, T cells are isolated from the human body and genetically engineered in vitro to express CAR and form CAR-T cells, which are then massively expanded in vitro and reinfused into the patient’s body. These CAR-T cells specifically recognize target antigens, proliferate rapidly, and exert anti-tumor effects in vivo. (B) CTLA-4 mAbs preferentially bind CTLA-4, and the ligand CD80/86, which has a stronger affinity for CTLA-4, binds CD80, thus restoring the normal function of T cells and leading to a transition from suppression of anti-tumor immunity to promotion of tumor immunity. (C) Nano-delivered drugs are degraded after being injected into the body and subsequently reach specific target sites, thereby stimulating the secretion of inflammatory factors and cytokines. This nano-delivery system improves tumor immunity efficacy. (D) After infection of tumor cells and normal cells with natural or genetically engineered oncolytic viruses (OVs), normal cells are not affected, whereas OV specifically targets tumor cells and proliferates in them, thus causing tumor cells to undergo lysis, apoptosis, and activating DC cells, NK cells, and cytotoxic T lymphocytes (CTLs) for further attack on tumor cells.
Newswise — Immunotherapy, especially immune checkpoint blockade (ICB), has transformed cancer treatment. However, many patients develop resistance to current treatments like anti-PD-1 and anti-CTLA-4. This resistance underscores the need for ongoing research to discover new immune checkpoint targets and enhance treatment efficacy. Based on these challenges, it is crucial to conduct in-depth studies to identify additional immune checkpoint inhibitors (ICIs) and develop combination therapies that can provide more effective cancer treatments.
Researchers from Guangdong Pharmaceutical University published a comprehensive review (DOI:10.20892/j.issn.2095-3941.2024.0055) in Cancer Biology & Medicine on May 24, 2024, highlighting recent progress in ICIs. The study, led by Xueqing Kong and colleagues, discusses novel immune checkpoint molecules and their clinical applications, aiming to improve cancer treatment outcomes.
The study explores the mechanisms behind resistance to current ICIs like anti-PD-1 and anti-CTLA-4 therapies. Researchers have identified new immune checkpoints, including T cell immunoreceptor with Ig and ITIM domains (TIGIT), T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), and lymphocyte activation gene-3 (LAG-3), which help tumors evade the immune system. Monoclonal antibodies targeting these molecules are in development and show promise for enhancing existing treatments. The review also highlights the benefits of combination therapies, such as pairing PD-1 inhibitors with anti-angiogenic agents, radiotherapy, or chemotherapy. These combined approaches have demonstrated improved outcomes in clinical trials. By integrating these new targets and strategies, the study aims to overcome the limitations of current ICIs, offering renewed hope and more effective options for cancer patients.
Dr. Rongxin Zhang, a leading immunologist at Guangdong Pharmaceutical University, commented, "The identification of new immune checkpoint targets marks a significant advancement in cancer immunotherapy. By understanding and targeting these novel molecules, we can develop more effective treatment strategies and overcome resistance mechanisms, ultimately improving patient outcomes."
The advancements in ICIs not only enhance current cancer treatment protocols but also pave the way for personalized medicine. By combining ICIs with other therapeutic modalities, researchers aim to create tailored treatment plans that address individual patient needs. These developments hold promise for reducing cancer recurrence rates and improving the overall survival of cancer patients.
###
References
DOI
10.20892/j.issn.2095-3941.2024.0055
Original Source URL
https://doi.org/10.20892/j.issn.2095-3941.2024.0055
Funding information
This study was supported by the National Natural Science Foundation of China (Grant Nos. 82173087 and 82203533).
About Cancer Biology & Medicine
Cancer Biology & Medicine (CBM) is a peer-reviewed open-access journal sponsored by China Anti-cancer Association (CACA) and Tianjin Medical University Cancer Institute & Hospital. The journal monthly provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The journal is indexed in SCOPUS, MEDLINE and SCI (IF 5.6, 5 year IF 5.9), with all full texts freely visible to clinicians and researchers all over the world.
RSS